NCCN task force report: Bone health in cancer care

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue SUPPL.3, 2013, Pages

  Gralow, Julie R ^a   Biermann, J Sybil ^b   Farooki, Azeez ^c   Fornier, Monica N ^c   Gagel, Robert F ^d   Kumar, Rashmi ^e   Litsas, Georgia ^f   McKay, Rana ^d   Podoloff, Donald A ^d   Srinivas, Sandy ^g   Van Poznak, Catherine H ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e National Comprehensive Cancer Network   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ALENDRONIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; CALCITONIN; CALCIUM; CLODRONIC ACID; DASATINIB; DENOSUMAB; DOCETAXEL; ERGOCALCIFEROL; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; RADIOPHARMACEUTICAL AGENT; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIPULEUCEL T; TAMOXIFEN; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ARTICLE; BONE; BONE BIOPSY; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER CARE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTERNAL BEAM RADIOTHERAPY; FEMUR FRACTURE; FEVER; FRAGILITY FRACTURE; GALLBLADDER DISEASE; HEALTH CARE; HEART ATRIUM FIBRILLATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; LEG CRAMP; LIFESTYLE MODIFICATION; MINIMALLY INVASIVE PROCEDURE; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; OVARY INSUFFICIENCY; PATHOLOGIC FRACTURE; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE FRACTURE; STEREOTACTIC BODY RADIATION THERAPY; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE AND BONES; BONE DENSITY; CALCIUM; DIETARY SUPPLEMENTS; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; OSTEOPOROSIS; RISK ASSESSMENT; VITAMIN D;

EID: 84887388574     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0215     Document Type: Article

References (382)

1. Nordin C. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011; 155: 276; author reply 276-277.
2. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-1194.
3. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-589.
4. Kanis JA, McCloskey E V, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999; 79: 1179-1181.
5. Chen Z, Maricic M, Bassford T.L., et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative observational study. Arch Intern Med 2005; 165: 552-558.
6. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
7. Cauley JA, Hochberg MC, Lui L.Y., et al. Long-term risk of incident vertebral fractures. JAMA 2007; 298: 2761-2767.
8. Njeh C.F., Fuerst T, Hans D., et al. Radiation exposure in bone mineral density assessment. Appl Radiat Isot 1999; 50: 215-236.
9. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011; 154: 356-364.
10. Hillner BE, Ingle JN, Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
11. Mohler JL, Armstrong AJ, Bahnson R.R., et al. NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer. Version 2, 2013. Available at: NCCN.org. Accessed June 18, 2013.
12. Theriault RL, Carlson RW, Allred C, et al. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. Version 3, 2013. Available at: NCCN.org. Accessed June 18, 2013.
13. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/tool.jsp. Accessed July 17, 2013.
14. Institute for Clinical Systems Improvement (ICSI). Diagnosis and treatment of osteoporosis. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2011. Available at: http://guideline.gov/content.aspx?id= 34270. Accessed July 17, 2013.
15. Garnero P, Sornay-Rendu E, Claustrat B., Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536.
16. Ross PD, Kress BC, Parson R.E., et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11: 76-82.
17. Sornay-Rendu E., Munoz F, Garnero P., et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20: 1813-1819.
18. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17: 505S-511S.
19. Cauley JA, Palermo L, Vogt M., et al. Prevalent vertebral fractures in black women and white women. J Bone Miner Res 2008; 23: 1458-1467.
20. Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992; 13(SUPPL. 2):S27-31.
21. Kuet K.P., Charlesworth D, Peel N F. Vertebral fracture assessment scans enhance targeting of investigations and treatment within a fracture risk assessment pathway. Osteoporos Int 2013; 24: 1007-1014.
22. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14: 821-828.
23. Melton LJ, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10: 214-221.
24. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
25. Genant HK, Li J, Wu C.Y., Shepherd JA. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 2000; 3: 281-290.
26. Lentle BC, Brown JP, Khan A, et al. Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J 2007; 58: 27-36.
27. Vokes T, Bachman D, Baim S., et al. Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom 2006; 9: 37-46.
28. Robb-Nicholson C. Radiation risk from medical imaging. Harvard Health Publication. Available at: http://www.health.harvard.edu/newsletters/Harvard- Womens-Health-Watch/2010/October/radiation-risk-from-medical-imaging. Accessed July 17, 2013.
29. 4th ISCD Position Development Conference (Adult). The Inernational Society for Clinical Densitometry Web site. Available at: http://www.iscd.org/ official-positions/4th-iscd-position-development-conference-adult/. Accessed July 17, 2013
30. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16(SUPPL. 2):S175-181.
31. Fornier MN, Modi S, Panageas K.S., et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104: 1575-1579.
32. Petrek JA, Naughton MJ, Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045-1051.
33. Goodwin PJ, Ennis M, Pritchard K.I., et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-2370.
34. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343: 1086-1094.
35. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306-3311.
36. Bruning PF, Pit MJ, de Jong-Bakker M, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990; 61: 308-310.
37. Delmas PD, Balena R, Confravreux E., et al. Bisphosphonate rise-dronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-962.
38. Headley JA, Theriault RL, LeBlanc A.D., et al. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998; 16: 6-11.
39. Hershman DL, McMahon DJ, Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745.
40. Powles TJ, McCloskey E, Paterson A.H., et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90: 704-708.
41. Saarto T, Blomqvist C, Valimaki M., et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-1347.
42. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
43. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14: 1001-1006.
44. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13: 105-112.
45. Geisler J, King N, Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4: 2089-2093.
46. Geisler J, Haynes B, Anker G., et al. Influence of letrozole and an-astrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-757.
47. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 733-738.
48. Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 2010; 118: 294-299.
49. Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002; 57: 317-338.
50. Coates AS, Keshaviah A, Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
51. Coombes RC, Hall E, Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
52. Forbes J.F., Cuzick J, Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
53. Jakesz R, Jonat W, Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
54. Eastell R, Adams J, Clack G., et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011; 22: 857-862.
55. Thurlimann B, Keshaviah A, Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
56. Coleman RE, Banks LM, Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8: 119-127.
57. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
58. Goss PE, Ingle JN, Pritchard K.I., et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol 2013; 31: 1398-1404.
59. Hershman DL, Cheung AM, Chapman J.W., et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density: two-year results of the NCIC CTG MA.27 bone companion study [abstract]. J Clin Oncol 2011; 29: Abstract 518.
60. Meng M.V., Grossfeld GD, Sadetsky N, et al. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60: 7-11;discussion 11-12
61. Nadler M, Alibhai S, Catton P., et al. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 2013; 111: 1301-1309.
62. Guise TA, Oefelein MG, Eastham J.A., et al. Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007; 9: 163-180.
63. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56: 779-786.
64. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab 2012; 23: 576-581.
65. Mellstrom D, Vandenput L, Mallmin H., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23: 1552-1560.
66. Maillefert J.F., Sibilia J, Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-1222.
67. Mittan D, Lee S, Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656-3661.
68. Berruti A, Dogliotti L, Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-2367.
69. Daniell HW, Dunn SR, Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
70. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24-34.
71. Lee H, McGovern K, Finkelstein J.S., Smith MR. Changes in bone mineral density and body composition during initial and longterm gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633-1637.
72. Daniell HW, Dunn SR, Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
73. Diamond T, Campbell J, Bryant C., Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-1566.
74. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
75. Greenspan SL, Coates P, Sereika S.M., et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-6417.
76. Kiratli BJ, Srinivas S, Perkash I., Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132.
77. Shahinian VB, Kuo YF, Freeman J.L., Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
78. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139; discussion 139.
79. Clinician's guide to the prevention and treatment of osteoporosis. National Osteoporosis Foundation Web site. Available at: http://nof.org/files/ nof/public/content/resource/913/files/580.pdf. Accessed July 17, 2013.
80. Fatalities and injuries from falls among older adults-United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep 2006; 55: 1221-1224.
81. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288: 2300-2306.
82. Moyer VA. Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 197-204.
83. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006; 332: 571-574.
84. Sawka AM, Boulos P, Beattie K., et al. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol 2007; 60: 336-344.
85. Cameron ID, Kurrle SE, Quine S, et al. Improving adherence with the use of hip protectors among older people living in nursing care facilities: a cluster randomized trial. J Am Med Dir Assoc 2011; 12: 50-57.
86. Cameron ID, Kurrle S, Quine S., et al. Increasing adherence with the use of hip protectors for older people living in the community. Osteoporos Int 2011; 22: 617-626.
87. Schaafsma FG, Kurrle SE, Quine S, et al. Wearing hip protectors does not reduce health-related quality of life in older people. Age Ageing 2012; 41: 121-125.
88. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642.
89. Dawson-Hughes B., Harris SS, Krall E.A., Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
90. Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 2997-3006.
91. Dietary reference intakes for calcium and vitamin D. Institute of Medicine Web site. Available at: http://www.iom.edu/Reports/2010/Dietary- Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. Accessed July, 17, 2013.
92. Curhan GC, Willett WC, Speizer F.E., et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126: 497-504.
93. Bolland MJ, Avenell A, Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.
94. Hennekens CH, Barice EJ. Calcium supplements and risk of myocardial infarction: a hypothesis formulated but not yet adequately tested. Am J Med 2011; 124: 1097-1098.
95. Adams JS, Kantorovich V, Wu C., et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab 1999; 84: 2729-2730.
96. Bischoff-Ferrari H.A., Dawson-Hughes B, Willett W.C., et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.
97. Rosen CJ, Gallagher JC. The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011; 14: 79-84.
98. Camacho PM, Dayal AS, Diaz J.L., et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008; 26: 5380-5385.
99. Crew KD, Shane E, Cremers S., et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; 27: 2151-2156.
100. Varsavsky M, Reyes-Garcia R, Cortes-Berdonces M, et al. Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer. Endocrinol Nutr 2011; 58: 487-491.
101. Holick M.F., Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
102. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 2007: 1-235.
103. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84: 694-697.
104. Holick MF, Biancuzzo RM, Chen T.C., et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-681.
105. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
106. Greenspan SL, Nelson JB, Trump D.L., Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424.
107. Van Poznak C. Managing bone mineral density with oral bisphos-phonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Res 2010; 12: 110.
108. Van Poznak C., Hannon RA, Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28: 967-975.
109. Siris ES, Harris ST, Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-1022.
110. Khan MN, Khan AA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol 2008; 15: 30-40.
111. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
112. Orwoll E, Teglbjaerg CS, Langdahl B.L., et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97: 3161-3169.
113. Smith MR, Saad F, Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 2670-2675.
114. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
115. Stopeck AT, Lipton A, Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
116. Stopeck A. Denosumab fndings in metastatic breast cancer. Clin Adv Hematol Oncol 2010; 8: 159-160.
117. Rossouw JE, Anderson GL, Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
118. Questions and answers for estrogen and estrogen with progestin therapies for postmenopausal women (updated). U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm135339.htm. Accessed June 18, 2013.
119. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-455.
120. Christin-Maitre S. The role of hormone replacement therapy in the management of premature ovarian failure. Nat Clin Pract Endocrinol Metab 2008; 4: 60-61.
121. Ettinger B, Black DM, Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282: 637-645.
122. Barrett-Connor E., Mosca L, Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
123. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmeno-pausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
124. Yalcin B, Buyukcelik A, Yalcin S., et al. Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2005; 97: 542; author reply 542-543.
125. Vogel VG, Costantino J P, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
126. Barrett-Connor E., Mosca L, Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
127. Cauley JA, Norton L, Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-134.
128. O'Regan R.M., Gajdos C, Dardes R.C., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94: 274-283.
129. Stewart HJ, Forrest A P, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-299.
130. Eng-Wong J., Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006; 91: 3941-3946.
131. Baum M, Buzdar A, Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-1810.
132. Farooki A, Fornier M, Girotra M. Anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 2410-2411.
133. MacLean C, Newberry S, Maglione M., et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197-213.
134. Cranney A, Tugwell P, Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540-551.
135. Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/UCM341779.pdf. Accessed July 17, 2013.
136. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008; 112: 1001-1010.
137. Gnant M, Mlineritsch B, Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
138. Shapiro CL, Halabi S, Hars V., et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47: 683-689.
139. Smith MR, Eastham J, Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
140. Smith MR, Morton RA, Barnette K.G., et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316-1321.
141. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
142. Grigg A.P., Shuttleworth P, Reynolds J., et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006; 91: 3835-3843.
143. Tauchmanovà L, Colao A, Lombardi G, et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 2007; 92: 4536-4545.
144. Tauchmanova L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 81-88.
145. Brown JE, Ellis S P, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007; 13: 5406-5410.
146. Grey A, Bolland MJ, Wattie D, et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94: 538-544.
147. Hershman DL, McMahon DJ, Crew K.D., et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010; 95: 559-566.
148. Lester JE, Dodwell D, Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
149. Brufsky AM, Harker WG, Beck J.T., et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118: 1192-1201.
150. Llombart A, Frassoldati A, Paija O., et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12: 40-48.
151. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zole-dronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
152. Fuleihan Gel H., Salamoun M, Mourad Y.A., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premeno-pausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 3209-3214.
153. Hines SL, Mincey BA, Sloan J.A., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009; 27: 1047-1053.
154. Ripps BA, VanGilder K, Minhas B., et al. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 2003; 48: 761-766.
155. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849.
156. Brown JE, Sherriff JM, James ND. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem. BJU Int 2010; 105: 1042-1043.
157. Lee CE, Leslie WD, Czaykowski P, et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol 2011; 18:e163-172.
158. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
159. Smith MR, McGovern FJ, Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
160. Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zole-dronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009; 182: 2257-2264.
161. Greenspan SL, Nelson JB, Trump D.L., et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426-4434.
162. Klotz LH, McNeill IY, Kebabdjian M, et al. A phase 3, doubleblind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol 2012; 63: 927-935.
163. Serpa Neto A., Tobias-Machado M, Esteves M.A., et al. Bisphos-phonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44.
164. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-3846.
165. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179: 152-155.
166. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:
167. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer [abstract]. Cancer Res 2011; 71(24 Suppl): Abstract S1-2.
168. Davies C, Pan H, Godwin J., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816.
169. Powles TJ, Hickish T, Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
170. Vehmanen L, Elomaa I, Blomqvist C., Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24: 675-680.
171. Lester JE, Dodwell D, Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
172. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009; 10: 2303-2315.
173. Sheehy O, Kindundu C, Barbeau M., LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 2009; 20: 1583-1594.
174. Weycker D, Lamerato L, Schooley S., et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int 2013; 24: 1483-1489.
175. Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012; 50: 870-875.
176. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2012; 23: 597-604.
177. Boissier S, Ferreras M, Peyruchaud O., et al. Bisphosphonates in-hibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954.
178. Senaratne SG, Pirianov G, Mansi J.L., et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-1468.
179. Teronen O, Konttinen YT, Salo T, et al. Bisphosphonates inhibit matrix metalloproteinases - a new possible mechanism of action. Duodecim 1999; 115: 13-15.
180. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698-705.
181. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99: 322-330.
182. Fournier P, Boissier S, Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544.
183. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551-3557.
184. Powles T, Paterson S, Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-3224.
185. Powles T, Paterson A, McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8:R13.
186. Diel IJ, Solomayer E F, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
187. Diel IJ, Jaschke A, Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 19: 2007-2011.
188. Saarto T, Blomqvist C, Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10-17.
189. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007; 96: 1796-1801.
190. Paterson AH, Anderson SJ, Lembersky B.C., et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
191. Möbus V., Diel I, Harbeck N., et al. GAIN study: a phase III trial to compare ETC vs. EC-TX and iIbandronate vs. observation in patients with node-positive primary breast cancer-1st interim efficacy analysis [abstract]. Cancer Res 2011; 71(24 Suppl): Abstract S2-4.
192. Coleman RE, Marshall H, Cameron D., et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
193. Gregory W, Marshall H, Bell R., et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract 513.
194. Goss PE, Barrios CH, Bell R, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled phase III clinical trial [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract TPS670.
195. Smith MR, Kabbinavar F, Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925.
196. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized doubleblind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99: 765-776.
197. Smith MR, Saad F, Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
198. Saad F, Smith MR, Shore N.D., et al. Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics [abstract]. J Clin Oncol 2012; 30: Abstract 4510.
199. ZEUS study yields no survival benefits and positive results. European Association of Urology Web site. http://www.uroweb.org/eau-news/?no-cache= 1&aid=648. Accessed July 17, 2013
200. Li S, Peng Y, Weinhandl E.D., et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol 2012; 4: 87-93.
201. Msaouel P, Pissimissis N, Halapas A., Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 341-355.
202. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995; 18: 51-64.
203. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-425.
204. Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev 2012; 32: 611-636.
205. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
206. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s-6216s.
207. Kingsley LA, Fournier PG, Chirgwin J.M., Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609-2617.
208. Braun S, Pantel K, Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
209. Giuliano AE, Hawes D, Ballman K V, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011; 306: 385-393.
210. Lucci A, Hall CS, Lodhi A.K., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13: 688-695.
211. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
212. Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Clin Cancer Res 2011; 17: 2967-2976.
213. Wiedswang G, Borgen E, Karesen R., et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004; 10: 5342-5348.
214. Meng S, Tripathy D, Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101: 9393-9398.
215. Roudier M.P., Vesselle H, True L.D., et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20: 171-180.
216. Hsu H, Lacey DL, Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-3545.
217. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-28.
218. Street J, Bao M, de Guzman L., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002; 99: 9656-9661.
219. Dai J, Kitagawa Y, Zhang J., et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004; 64: 994-999.
220. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
221. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
222. Sathiakumar N, Delzell E, Morrisey M.A., et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat 2012; 131: 231-238.
223. Sathiakumar N, Delzell E, Morrisey M.A., et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14: 177-183.
224. Lage MJ, Barber BL, Harrison D.J., Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317-322.
225. Pockett RD, Castellano D, McEwan P., et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010; 19: 755-760.
226. Roberts CC, Daffner RH, Weissman B.N., et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol 2010; 7: 400-409.
227. Hamaoka T, Madewell JE, Podoloff D.A., et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22: 2942-2953.
228. Durning P, Best JJ, Sellwood RA. Recognition of metastatic bone disease in cancer of the breast by computed tomography. Clin Oncol 1983; 9: 343-346.
229. Muindi J, Coombes RC, Golding S, et al. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983; 56: 233-236.
230. Hanna SL, Fletcher BD, Fairclough D.L., et al. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol 1991; 20: 79-84.
231. Avrahami E, Tadmor R, Dally O., Hadar H. Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans. J Comput Assist Tomogr 1989; 13: 598-602.
232. Frank JA, Ling A, Patronas N.J., et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol 1990; 155: 1043-1048.
233. Ma J, Costelloe CM, Madewell J.E., et al. Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 2009; 29: 1154-1162.
234. Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999; 23: 123-129.
235. Schmidt G.P., Baur-Melnyk A, Haug A., et al. Comprehensive imaging of tumor recurrence in breast cancer patients using wholebody MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008; 65: 47-58.
236. Krishnamurthy GT, Tubis M, Hiss J., Blahd WH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 1977; 237: 2504-2506.
237. Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 2008; 15: 311-323.
238. Daldrup-Link H.E., Franzius C, Link T.M., et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177: 229-236.
239. Ohta M, Tokuda Y, Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.
240. Kao CH, Hsieh JF, Tsai S.C., et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20: 2189-2192.
241. Dehdashti F, Flanagan FL, Mortimer J.E., et al. Positron emission tomographic assessment of "metabolic flare," to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26: 51-56.
242. Mortimer JE, Dehdashti F, Siegel B.A., et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-2803.
243. Costelloe CM, Rohren EM, Madewell J.E., et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009; 10: 606-614.
244. Han LJ, Au-Yong TK, Tong W.C., et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 1998; 25: 635-638.
245. Romer W, Nomayr A, Uder M., et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006; 47: 1102-1106.
246. Ndlovu X, George R, Ellmann A., Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 2010; 31: 659-665.
247. Hilton JF, Amir E, Hopkins S., et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat 2011; 129: 761-765.
248. Schneider JA, Divgi CR, Scott A.M., et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994; 35: 1748-1752.
249. Stafford SE, Gralow JR, Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9: 913-921.
250. Therasse P, Arbuck SG, Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
251. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
252. Conte PF, Latreille J, Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14: 2552-2559.
253. Dearnaley DP, Mason MD, Parmar M.K., et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876.
254. Morgan GJ, Davies FE, Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.
255. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003; 97: 848-853.
256. Hirsh V, Major P P, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228-236.
257. Lipton A, Theriault RL, Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082-1090.
258. Major P, Lortholary A, Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567.
259. Rosen LS, Gordon D, Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
260. Kohno N, Aogi K, Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314-3321.
261. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
262. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
263. Coleman RE, Wright J, Houston S., et al. Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract 511.
264. Amadori D, Aglietta M, Alessi B., et al. ZOOM: a prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract 9005.
265. Fizazi K, Lipton A, Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
266. Van Poznak C.H., Temin S, Yee G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in meta-static breast cancer. J Clin Oncol 2011; 29: 1221-1227.
267. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
268. Prolia [package insert]. Thousand Oaks, CA: Amgen Inc.; 2011
269. Josson S, Matsuoka Y, Chung L.W., et al. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 2010; 21: 26-32.
270. Petrylak D.P., Tangen CM, Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
271. de Bono J.S., Oudard S, Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
272. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
273. Scher HI, Fizazi K, Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
274. Costa L, Badia X, Chow E., et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008; 16: 879-889.
275. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970.
276. Halabi S, Vogelzang NJ, Kornblith A.B., et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26: 2544-2549.
277. Fizazi K, Massard C, Smith M.R., et al. Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer [abstract]. J Clin Oncol 2012; 30: Abstract 4642.
278. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
279. Higano CS, Schellhammer PF, Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
280. Kantoff PW, Higano CS, Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
281. Small EJ, Schellhammer PF, Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
282. Kawalec P, Paszulewicz A, Holko P., Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci 2012; 8: 767-775.
283. Logothetis C, De Bono JS, Molina A, et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): results from the COU-AA-301 phase III study [abstract]. J Clin Oncol 2011; 29: Abstract 4520.
284. Logothetis CJ, Basch E, Molina A., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217.
285. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract LBA4518.
286. Cook RJ, Coleman R, Brown J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12: 3361-3367.
287. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
288. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
289. Fizazi K, Carducci M, Smith M., et al. Denosumab versus zole-dronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
290. Sartor AO, Heinrich D, O'Sullivan JM, et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA) [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract 4551.
291. Yu EY, Massard C, Gross M.E., et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77: 1166-1171.
292. Araujo JC, Mathew P, Armstrong A.J., et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118: 63-71.
293. Yakes FM, Chen J, Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10: 2298-2308.
294. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]. J Clin Oncol 2011; 29(Suppl): Abstract 4516.
295. Smith MR, Sweeney C, Rathkopf D.E., et al. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II non-randomized expansion cohort (NRE) [abstract]. J Clin Oncol 2012; 30(Suppl): Abstract 4513.
296. Xie J, Namjoshi M, Wu E.Q., et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011; 17: 621-643.
297. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137.
298. Body J-J, Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 306-312.
299. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-2430.
300. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869-1876.
301. Rosen LS, Gordon D, Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
302. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013; 119: 832-838.
303. Chow E, Harris K, Fan G., et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-1436.
304. Wu JS-Y, Wong R., Johnston M, et al. Meta-analysis of dosefractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605.
305. Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastases: an overview. Neurosurg Focus 2001; 11:e10.
306. Hartsell WF, Scott CB, Bruner D.W., et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798-804.
307. Chow E, Zeng L, Salvo N., et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012; 24: 112-124.
308. Lutz S, Berk L, Chang E., et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-976.
309. Howell DD, James JL, Hartsell W.F., et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer 2013; 119: 888-896.
310. Zeng L, Chow E, Bedard G., et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys 2012; 84:e337-342.
311. van den Hout WB, van der Linden YM, Steenland E, et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-229.
312. Bradley NM, Husted J, Sey M.S., et al. Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer 2007; 15: 373-385.
313. Hird A, Chow E, Zhang L., et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys 2009; 75: 193-197.
314. Gerszten PC, Burton SA, Welch W.C., et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 2005; 104: 2244-2254.
315. Malviya A, Gerrand C. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med 2012; 26: 788-796.
316. Ward WG, Holsenbeck S, Dorey F.J., et al. Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res 2003:S230-244.
317. Van der Linden YM, Dijkstra PD, Kroon H.M., et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 2004; 86: 566-573.
318. Franck WM, Olivieri M, Jannasch O., Hennig FF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg 2002; 122: 400-405.
319. Redmond BJ, Biermann JS, Blasier RB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am 1996; 78: 891-896.
320. Gregory JJ, Ockendon M, Cribb G.L., et al. The outcome of locking plate fixation for the treatment of periarticular metastases. Acta Orthop Belg 2011; 77: 362-370.
321. Moholkar K, Mohan R, Grigoris P. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004; 70: 429-434.
322. Samsani SR, Panikkar V, Venu K.M., et al. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004; 30: 993-997.
323. Marco RA, Sheth DS, Boland P.J., et al. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000; 82: 642-651.
324. Benevenia J, Cyran F P, Biermann JS, et al. Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res 2004: 23-31.
325. Goetz MP, Callstrom MR, Charboneau J.W., et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004; 22: 300-306.
326. Tancioni F, Lorenzetti MA, Navarria P, et al. Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 2011; 9: 4-10.
327. Peh WC, Gilula LA. Percutaneous vertebroplasty: indications, contraindications, and technique. Br J Radiol 2003; 76: 69-75.
328. Lee B, Franklin I, Lewis J.S., et al. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer 2009; 45: 1597-1602.
329. Saliou G, Kocheida el M, Lehmann P, et al. Percutaneous verte-broplasty for pain management in malignant fractures of the spine with epidural involvement. Radiology 2010; 254: 882-890.
330. Chew C, Craig L, Edwards R., et al. Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review. Clin Radiol 2011; 66: 63-72.
331. Fourney DR, Schomer DF, Nader R, et al. Percutaneous verte-broplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98: 21-30.
332. Lane JM, Hong R, Koob J., et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 2004: 49-53.
333. Qian Z, Sun Z, Yang H., et al. Kyphoplasty for the treatment of malignant vertebral compression fractures caused by metastases. J Clin Neurosci 2011; 18: 763-767.
334. Kelekis A, Lovblad KO, Mehdizade A, et al. Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interv Radiol 2005; 16: 81-88.
335. Callstrom MR, Charboneau JW, Goetz M.P., et al. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol 2006; 35: 1-15.
336. Hayat MJ, Howlader N, Reichman M.E., Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37.
337. Zairi F, Arikat A, Allaoui M., et al. Minimally invasive decompression and stabilization for the management of thoracolumbar spine metastasis. J Neurosurg Spine 2012; 17: 19-23.
338. Tanck E, van Aken JB, van der Linden YM, et al. Pathological fracture prediction in patients with metastatic lesions can be improved with quantitative computed tomography based computer models. Bone 2009; 45: 777-783.
339. Chang JT, Green L, Beitz J. Renal failure with the use of zole-dronic acid. N Engl J Med 2003; 349: 1676-1679.
340. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11: 81-88.
341. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95: 1555-1565.
342. Body JJ, Lipton A, Henry D., et al. Hypocalcemia in patients with metastatic bone disease receiving denosumab [abstract]. J Clin Oncol 2013; Suppl: Abstract 9628.
343. Autio K, Farooki A, Glezerman I., et al. Risk assessment for severe hypocalcemia requiring hospitalization with denosumab [abstract]. J Clin Oncol 2013; 31(Suppl): Abstract 115.
344. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
345. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188-2194.
346. Brufsky AM, Bosserman LD, Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009; 9: 77-85.
347. Brufsky A, Harker G, Beck J., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [abstract]. Cancer Res 2009; 69 (24 Suppl): Abstract 4083.
348. Tennis P, Rothman KJ, Bohn R.L., et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 2012; 21: 810-817.
349. Lipton A, Saad F, Van Poznak CH, et al. Incidence of osteone-crosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: results from three phase III trials [abstract]. J Clin Oncol 2013; (Suppl): Abstract 9640.
350. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009; 44: 4-10.
351. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg 2009; 67: 13-18.
352. Ruggiero SL, Carlson ER, Assael LA. Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient. J Oral Maxillofac Surg 2009; 67: 1.
353. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 2009; 60: 85-96.
354. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008; 13: 911-920.
355. Ruggiero SL, Dodson TB, Assael L.A., et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
356. Aragon-Ching J.B., Ning Y-M, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27: 221-226.
357. Christodoulou C, Pervena A, Klouvas G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76: 209-211.
358. Greuter S, Schmid F, Ruhstaller T., Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19: 2091-2092.
359. Wynn RL. Bevacizumab (Avastin): an anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent 2011; 59: 410-413.
360. Kwek EBK, Goh SK, Koh JSB, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39: 224-231.
361. Odvina C.V., Zerwekh JE, Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301.
362. Goh SK, Yang KY, Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349-353.
363. Neviaser AS, Lane JM, Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22: 346-350.
364. Goddard MS, Reid KR, Johnston J.C., Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009; 32.
365. Odvina C.V., Levy S, Rao S., et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010; 72: 161-168.
366. Prolia: package insert and label information. DrugInserts.com Web site. Available at: http://druginserts.com/lib/rx/meds/prolia/. Accessed June 18, 2013.
367. Dell RM, Adams AL, Greene D.F., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27: 2544-2550.
368. Giusti A, Hamdy NA, Dekkers O.M., et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011; 48: 966-971.
369. Feldstein AC, Black D, Perrin N., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27: 977-986.
370. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-1737.
371. Lo JC, Huang SY, Lee G.A., et al. Clinical correlates of atypical femoral fracture. Bone 2012; 51: 181-184.
372. Thompson RN, Phillips JR, McCauley S.H., et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012; 94: 385-390.
373. Shane E, Burr D, Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-2294.
374. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
375. Wilkinson GS, Baillargeon J, Kuo Y F, et al. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010; 28: 4898-4905.
376. Lipton A, Fizazi K, Stopeck A.T., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.
377. Skrepnek GH, Seal B, Tangirala M., et al. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent 2010; 58: 484-492.
378. Galvao DA, Taaffe DR, Cormie P, et al. Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer 2011; 11: 517.
379. Breen T, Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency [correspondence]. J Clin Oncol 2005: 1531-1532.
380. Adami S, Giannini S, Bianchi G., et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239-244.
381. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-1791.
382. Theriault RL, Lipton A, Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.